Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.
about
Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart diseaseHeart failure with preserved ejection fraction: emerging drug strategiesCardiopulmonary laboratory biomarkers in the evaluation of acute dyspneaPulmonary hypertension in patients with heart failure and preserved ejection fraction: differential diagnosis and managementTargeting heart failure with preserved ejection fraction: current status and future prospectsIs enhancing cGMP-PKG signalling a promising therapeutic target for heart failure with preserved ejection fraction?How to diagnose heart failure with preserved ejection fraction: the value of invasive stress testingUnderstanding heart failure with preserved ejection fraction: where are we today?Biomarkers in heart failure with preserved ejection fractionBreakthrough in heart failure with preserved ejection fraction: are we there yet?Left ventricular heart failure and pulmonary hypertensionReporting trends of randomised controlled trials in heart failure with preserved ejection fraction: a systematic reviewChallenging aspects of treatment strategies in heart failure with preserved ejection fraction: "Why did recent clinical trials fail?"Pulmonary hypertension: diagnostic and therapeutic challengesMyocardial hypertrophy and its role in heart failure with preserved ejection fractionAn official American Thoracic Society/American College of Chest Physicians policy statement: the Choosing Wisely top five list in adult pulmonary medicineCardiac endothelium-myocyte interaction: clinical opportunities for new heart failure therapies regardless of ejection fractionExercise intolerance in heart failure with preserved ejection fraction: more than a heart problemHeart failure with preserved ejection fraction: mechanisms, clinical features, and therapiesTherapeutic potential of PDE modulation in treating heart diseasePatient selection in heart failure with preserved ejection fraction clinical trialsExtending the translational potential of targeting NO/cGMP-regulated pathways in the CVSRight ventricular afterload and the role of nitric oxide metabolism in left-sided heart failureHeart failure with preserved ejection fractionThe cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fractionTargeting myocardial remodelling to develop novel therapies for heart failure: a position paper from the Working Group on Myocardial Function of the European Society of CardiologyMale and female hypertrophic rat cardiac myocyte functional responses to ischemic stress and β-adrenergic challenge are different.Inhibition of type 5 phosphodiesterase counteracts β2-adrenergic signalling in beating cardiomyocytesClinical Phenotypes in Heart Failure With Preserved Ejection FractionPathophysiological role of oxidative stress in systolic and diastolic heart failure and its therapeutic implicationsWhat global diastolic function is, what it is not, and how to measure itDiastolic dysfunctionThe emperor's new clothes: PDE5 and the heartSwimming-Induced Pulmonary Edema: Pathophysiology and Risk Reduction With Sildenafil.Sildenafil ameliorates left ventricular T-tubule remodeling in a pressure overload-induced murine heart failure modelShould there be sex-specific criteria for the diagnosis and treatment of heart failure?Cardiovascular Disease in Women: Clinical Perspectives.Cardiac magnetic resonance assessment of interstitial myocardial fibrosis and cardiomyocyte hypertrophy in hypertensive mice treated with spironolactone.Advances in the pathophysiology and treatment of heart failure with preserved ejection fractionSkeletal muscle abnormalities and exercise intolerance in older patients with heart failure and preserved ejection fraction.
P2860
Q24323316-7B80325F-752F-4425-BEE2-697CA8F3EB02Q24595118-E47FD6A8-76E8-46D6-8DC5-9FD035B89713Q26745756-131019B6-24ED-46B3-9F43-75A5D0BE563DQ26750994-9501AC95-6474-4251-98E7-177F528BEAC0Q26752956-376E5430-9C39-4E7E-A83C-58F60FD16DA3Q26765931-B4252D7E-DDE8-4876-B1BA-C2CF9F5B13EFQ26766355-5964B566-0491-49E6-AB17-C128654F18FCQ26766590-31F7899F-1386-4925-81CD-5219C4E23953Q26768192-A517ADAB-BB64-466A-82A5-66004B26090DQ26771999-E806329D-9B8E-42CA-B692-A69A7A03D1DCQ26778341-D53CF528-DBAE-4595-BDB5-406DAB163EE3Q26779538-6A3A0F03-BAD3-4A08-A263-270CB3A9B32FQ26785931-AFF422A5-4311-4587-9133-40C438917BCAQ26796434-7E54722E-6E35-4E86-8B7F-3BDE16958A77Q26800076-7EC54B22-4033-4854-AA6A-B2CB1588A1D3Q26829758-B0419EC0-30E0-49DA-86BC-05B3635A97FAQ26853363-941BB439-9EBB-43DF-AFDD-C39E6F12F27AQ26991985-A30D945D-6564-480A-B646-42FE3C32F1D6Q27000263-A8EA51EF-1A25-4610-A1FE-E3D4659C558EQ27005761-DE81D9C2-9877-46D7-99F1-56B559565844Q27015845-2A984DFE-F8B2-4D62-8494-5B1170450DD6Q27021649-C0D2E7F5-8570-4489-A62C-1FE8247C2F72Q27022359-C60AC2F9-DAB8-4665-BC57-FD7C3B8D2CABQ27024008-43628B0E-E298-42F0-9DD0-2E45508943C4Q27024279-5D959C30-65DD-4675-972F-AFEB5F00F4D9Q27024879-3F65B99A-3123-467F-978D-F0766973EC46Q27321564-5A215B1D-3EF2-4A4B-A0B2-7D4EA637E3A6Q27967859-CEC8B0FA-7CDD-49EB-8D17-5C1169959866Q28073079-DDC18CE7-D228-4905-86D5-076C6E401828Q28085102-76895720-3137-4C0E-B229-62BEE43B4C88Q28087043-42A244A6-8256-403E-8DA2-764B19B77093Q28087715-3396EB7F-0053-41E2-85BA-9C35288890BCQ28543897-7362D0DC-8FE2-4D38-BBDF-2386C4CB18CFQ30277332-6BCCAFDD-DA68-4599-A3FA-1E27CD947A4FQ30385717-57B03A6F-E8DF-49E0-9182-40DB705DD19FQ30442043-FB4B4957-1A9A-4137-8F9C-77FA37EAC4B6Q30743765-B165F4A6-2B64-4AC5-93D1-C5F49208A211Q30833375-93921511-00F4-458D-9D21-3E7FA8C3F8AFQ33565707-44D7B41F-B748-4865-99D0-0A59F0F91C54Q33568831-B9845481-6FB2-40F5-9C36-A05C70C13E29
P2860
Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Effect of phosphodiesterase-5 ...... : a randomized clinical trial.
@en
Effect of phosphodiesterase-5 ...... : a randomized clinical trial.
@nl
type
label
Effect of phosphodiesterase-5 ...... : a randomized clinical trial.
@en
Effect of phosphodiesterase-5 ...... : a randomized clinical trial.
@nl
prefLabel
Effect of phosphodiesterase-5 ...... : a randomized clinical trial.
@en
Effect of phosphodiesterase-5 ...... : a randomized clinical trial.
@nl
P2093
P2860
P50
P356
P1476
Effect of phosphodiesterase-5 ...... : a randomized clinical trial.
@en
P2093
Alice M Mascette
Anita Deswal
Barry A Borlaug
Bradley A Bart
David A Bull
Elizabeth O Ofili
Eric J Velazquez
G Michael Felker
Gregory Lewis
P2860
P304
P356
10.1001/JAMA.2013.2024
P407
P577
2013-03-01T00:00:00Z